Previous 10 | Next 10 |
home / stock / exai / exai articles
NEW YORK, May 03, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsu...
NEW YORK, May 03, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. ...
NEW YORK, May 03, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Exscientia plc ("Exscientia" or the "Comp...
NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, not...
SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons an...
NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces tha...
NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims...
NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Exscientia plc (NASDAQ:EXAI)? Did you pu...
ATLANTA, April 29, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Exscientia p.l.c. ("Exscientia" or the "Co...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 08:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Maximises upside potential of precision-designed GTAEXS617 with purchase of rights from GT Apeiron Monotherapy dose escalation data readout for ELUCIDATE Phase 1/2 trial on track for second half of 2024 Combination dose escalation study starting with HR+/HER2- breast cancer to com...
— State-of-the-art platform, built using Amazon Web Services technologies, integrates generative AI drug design and robotic lab automation to further accelerate Exscientia’s ability to deliver high quality drug candidates at faster speed and lower cost — Exscientia ...